GET DAILY SIGNALSWerewolf Therapeutics (HOWL) Holds Near $1.04 as Ambros Merger Nears
Key Takeaways
- HOWL shares traded near $1.04 in late October 2026, up roughly 8% from the $0.96 close of late September, keeping the 30-day move below the 10% threshold.
- The defining catalyst remains the August 21, 2026 all-stock reverse merger with Ambros Therapeutics, which pivots the company toward neridronate, a Phase 3 candidate for complex regional pain syndrome type 1 (CRPS-1).
- A concurrent $150 million private placement, co-led by RA Capital Management and Janus Henderson Investors, is expected to fund the combined company into the first half of 2029.
- On closing, expected by the first quarter of 2027, the combined company is slated to trade under the ticker AMBX, with pre-merger Werewolf holders owning about 6.8% plus a contingent value right.
- Werewolf separately agreed to sell its INDUCER and certain INDUKINE assets to EMD Serono for $28 million upfront plus up to $5 million.
- Second-quarter 2026 results showed net income of $3.67 million on $21.0 million in collaboration revenue from the JZP898 asset sale to Jazz Pharmaceuticals.
- For more detail, explore Werewolf's Price Targets, Earnings, and Forecast pages.
- You can also monitor how automated systems are positioning across the market by exploring Trending AI Robots.
Market Snapshot
Werewolf Therapeutics shares have settled into a range near the $1.00 level following the volatility of late August 2026. The stock closed around $1.04 on October 27, 2026, roughly 8% above the $0.96 level recorded in late September. Over the prior three months, the shares moved up sharply from the sub-$0.40 range seen in late July, with the bulk of that advance arriving in a single session tied to a corporate restructuring announcement. With a market capitalization near $50 million and a 52-week range spanning $0.27 to $1.72, the stock remains a low-float, event-driven name whose valuation is tightly linked to the outcome of a pending merger and the clinical progress of an acquired pipeline asset. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Company Background
Werewolf Therapeutics is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts. The company built its proprietary PREDATOR platform to design conditionally activated molecules intended to stimulate the immune system selectively within the tumor microenvironment. Its lead clinical programs are WTX-124, a conditionally activated Interleukin-2 (IL-2) INDUKINE, and WTX-330, an Interleukin-12 (IL-12) INDUKINE, both developed for solid tumors. The company has also advanced INDUCER T cell engager candidates targeting prostate, ovarian, and kidney cancers. Investors have historically followed the stock for its differentiated immuno-oncology approach, although the company's forward-looking value proposition is now being reshaped by its planned combination with Ambros Therapeutics.
Recent Developments
The most significant recent development is the definitive merger agreement with privately held Ambros Therapeutics, announced on August 21, 2026, alongside an oversubscribed $150 million private placement co-led by RA Capital Management and Janus Henderson Investors. The all-stock reverse merger values Ambros at approximately $500 million and refocuses the combined entity on neridronate, a bisphosphonate in a pivotal Phase 3 trial (CRPS-RISE) for CRPS-1, a debilitating orphan pain condition with no FDA-approved pharmacological therapy. Neridronate holds FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations, and the combined company anticipates topline trial data in 2028 with a planned New Drug Application submission.
In parallel, Werewolf agreed to sell its INDUCER platform and certain INDUKINE assets to EMD Serono, a unit of Merck KGaA, for $28 million upfront plus up to $5 million upon technology transfer, while retaining WTX-124 and WTX-330, whose future monetization is tied to a contingent value right. Earlier in 2026, the company completed a $21.0 million asset purchase agreement with Jazz Pharmaceuticals for the JZP898 program and repaid its debt facility with K2 HealthVentures. These steps produced a second-quarter net profit and extended the standalone company's cash runway into the second quarter of 2027.
2026 Outlook
Looking ahead, the primary focus for HOWL shareholders is the completion of the Ambros merger, which is expected to close by the first quarter of 2027 subject to stockholder approval, effectiveness of the Form S-4 registration statement, and Nasdaq listing clearance. Investors will also monitor the progress of the CRPS-RISE Phase 3 trial for neridronate, with topline results anticipated in 2028, as well as any updates on the contingent value right covering potential future monetization of WTX-124 and WTX-330. Key risks include the possibility that the merger does not close on the anticipated timeline, clinical or regulatory setbacks for neridronate, and broader volatility in the biotechnology sector. As with any event-driven micro-cap, near-term share movements may continue to reflect deal execution and financing milestones rather than underlying fundamentals. From what I see, this remains an event-driven story where timing of the close will matter most.
AI Tools in My Research Process
One resource I turn to regularly when reviewing names like this is Tickeron’s AI Trading Bots. The platform lets me review how different automated strategies have performed across a wide range of tickers and timeframes, which adds another layer to my own fundamental review without replacing it. It is not a recommendation, simply a way to see what systematic approaches are highlighting at any given moment. You can browse the full selection on the Trending AI Robots page.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HOWL sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for HOWL moved above the 200-day moving average on September 23, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on HOWL as a result. In 66 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
Following a +6.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where HOWL advanced for three days, in 201 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 118 of 137 cases where HOWL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Bearish Trend Analysis
The 10-day RSI Indicator for HOWL moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 23 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 54 cases where HOWL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for HOWL turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 38 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HOWL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
HOWL broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. HOWL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.102) is normal, around the industry mean (2.974). P/E Ratio (-1.444) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (2.169) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HOWL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement